Browsing by Yonsei Author : Shin, Sang Joon

eperson profile image
Name:
Shin, Sang Joon [신상준]
orcid http://orcid.org/0000-0001-5350-7241
Department :
College of Medicine (의과대학) - Dept. of Internal Medicine (내과학교실)
Scopus ID :
Scopus (7403647334)

Keyword Cloud

Researcher Network

Showing results 1 to 50 of 180

This table browses all dspace content
Issue DateTitleJournal Title
2024Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma ONCOLOGIST
2024Nuclear Localization of Yes-Associated Protein Is Associated With Tumor Progression in Cutaneous Melanoma LABORATORY INVESTIGATION
2024Pembrolizumab with or Without Lenvatinib as First-line Therapy for Patients with Advanced Urothelial Carcinoma (LEAP-011): A Phase 3, Randomized, Double-Blind Trial EUROPEAN UROLOGY
2023Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study JOURNAL OF CLINICAL ONCOLOGY
2023Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma)CLINICAL CANCER RESEARCH
2023Active involvement of patients, radiation oncologists, and surgeons in a multidisciplinary team approach: Guiding local therapy in recurrent, metastatic rectal cancer CANCER MEDICINE
2023A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13) EUROPEAN JOURNAL OF CANCER
2023A prospective, multicenter study on the clinical effectiveness of abiraterone in metastatic castration-resistant prostate cancer in Korea: Pre- vs. post-chemotherapy INVESTIGATIVE AND CLINICAL UROLOGY
2023A Phase Ib, Open-label Study Evaluating the Safety and Efficacy of Ipatasertib plus Rucaparib in Patients with Metastatic Castration-resistant Prostate CancerCLINICAL CANCER RESEARCH
2023Effect of High-Versus Low-Frequency of Abdominopelvic Computed Tomography Follow-Up Testing on Overall Survival in Patients With Stage II Or III Colon CancerCLINICAL COLORECTAL CANCER
2023Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial JOURNAL OF CLINICAL ONCOLOGY
2023Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18 ESMO OPEN
2023Hepatic arterial infusion in combination with systemic chemotherapy in patients with hepatic metastasis from colorectal cancer: a randomized phase II study – (NCT05103020) – study protocol BMC CANCER
2023Importance of Local Ablative Therapies for Lung Metastases in Patients With Colorectal CancerANNALS OF SURGERY
2023Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study CANCER RESEARCH AND TREATMENT
2023Short-Term Outcomes and Cost-Effectiveness between Long-Course Chemoradiation and Short-Course Radiotherapy for Locally Advanced Rectal Cancer YONSEI MEDICAL JOURNAL
2023Mathematical prediction with pretreatment growth rate of metastatic cancer on outcomes: implications for the characterization of oligometastatic disease FRONTIERS IN ONCOLOGY
2023Safety and efficacy of cobimetinib plus atezolizumab in patients with solid tumors: a phase II, open-label, multicenter, multicohort study ESMO OPEN
2023Real-World Study Evaluating Safety and Effectiveness of Axitinib in Korean Patients with Renal Cell Carcinoma after Failure of One Prior Systemic Therapy CANCER RESEARCH AND TREATMENT
2023Fusobacterium nucleatum induces a tumor microenvironment with diminished adaptive immunity against colorectal cancers FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
2023Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma JOURNAL OF CLINICAL ONCOLOGY
2023Outcomes of an Acute Palliative Care Unit at a Comprehensive Cancer Center in Korea PALLIATIVE MEDICINE REPORTS
2023Machine Learning-Based Mortality Prediction Model for Critically Ill Cancer Patients Admitted to the Intensive Care Unit (CanICU) CANCERS
2022A Comparison of 2 Disease Burden Assessment Methods (3D Volume Versus the Number of Lesions) for Prognostication of Survival in Metastatic Melanoma: Implications for the Characterization of Oligometastatic DiseaseINTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
2022Oxaliplatin (3 months v 6 months) With 6 Months of Fluoropyrimidine as Adjuvant Therapy in Patients With Stage II/III Colon Cancer: KCSG CO09-07JOURNAL OF CLINICAL ONCOLOGY
2022Feasibility of using dental putty-based custom molds for high-dose-rate brachytherapy of oral mucosal melanomaPHYSICA MEDICA-EUROPEAN JOURNAL OF MEDICAL PHYSICS
2022First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanomaJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
2022A phase II study to evaluate the efficacy of regorafenib in C-KIT mutated metastatic malignant melanoma patients who have progressed on first-line treatment: A Multicenter Trial of Korean Cancer Study Group (UN-14–13)EUROPEAN JOURNAL OF CANCER
2022Enfortumab vedotin-related pneumonitis is more common than expected and could lead to acute respiratory failureEUROPEAN JOURNAL OF CANCER
2022The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression ESMO OPEN
2022Periodontal disease and cancer risk: A nationwide population-based cohort study FRONTIERS IN ONCOLOGY
2022KS10076, a chelator for redox-active metal ions, induces ROS-mediated STAT3 degradation in autophagic cell death and eliminates ALDH1 + stem cells CELL REPORTS
2022The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
2022Application of Multigene Panel Testing in Patients With High Risk for Hereditary Colorectal Cancer: A Descriptive Report Focused on Genotype-Phenotype CorrelationDISEASES OF THE COLON & RECTUM
2022Metastasis-Directed Radiotherapy for Oligoprogressive or Oligopersistent Metastatic Colorectal CancerCLINICAL COLORECTAL CANCER
2022Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors CANCERS
2022Association of neutrophil-to-lymphocyte ratio, radiotherapy fractionation/technique, and risk of development of distant metastasis among patients with locally advanced rectal cancer RADIATION ONCOLOGY
2022Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma EUROPEAN JOURNAL OF CANCER
2022First-line pembrolizumab (pembro) with or without lenvatinib (lenva) in patients with advanced urothelial carcinoma (LEAP-011): A phase 3, randomized, double-blind study.JOURNAL OF CLINICAL ONCOLOGY
2022A phase Ib, open-label study evaluating the safety and efficacy of ipatasertib + rucaparib in patients with metastatic castration-resistant prostate cancerJOURNAL OF CLINICAL ONCOLOGY
2022Suppression of DYRK1A/B Drives Endoplasmic Reticulum Stress-mediated Autophagic Cell Death Through Metabolic Reprogramming in Colorectal Cancer CellsANTICANCER RESEARCH
2021Deep-Learning-Based Natural Language Processing of Serial Free-Text Radiological Reports for Predicting Rectal Cancer Patient Survival FRONTIERS IN ONCOLOGY
2021Upfront chemotherapy and short-course radiotherapy with delayed surgery for locally advanced rectal cancer with synchronous liver metastasesEJSO
2021A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancerINVESTIGATIONAL NEW DRUGS
2021Ferroportin and FBXL5 as Prognostic Markers in Advanced Stage Clear Cell Renal Cell Carcinoma CANCER RESEARCH AND TREATMENT
2021Synthesis of novel 1H-Pyrazolo[3,4-b]pyridine derivatives as DYRK 1A/1B inhibitorsBIOORGANIC & MEDICINAL CHEMISTRY LETTERS
2021Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection WORLD ALLERGY ORGANIZATION JOURNAL
2021Patterns of Locoregional Recurrence after Radical Cystectomy for Stage T3-4 Bladder Cancer: A Radiation Oncologist's Point of View YONSEI MEDICAL JOURNAL
2021ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanomaNATURE
2021The Awareness and Usage of Big Data for Cancer in Korea: A Survey Study Journal of Health Informatics and Statistics(보건정보통계학회지)

Browse

Links